Company / Shareholders' Equity
CytomX Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$99.0M
FY2025
5-year range
-$85.8M / $99.0M
FY2021-FY2025
Trend
+21812.3%
vs FY2024
Sector context
#172 of 213
Health Care
What the data says
Shareholders' Equity changed +21812% YoY in FY2025, a notable deviation from the 9-year average annual change of +374%.
Based on SEC 10-K filings.
$99M in FY2025.
Improved from -$47M to $99M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 213This company $99.0M Sector average $2.5B
▼
-96.1% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s shareholders' equity has grown for 3 consecutive years.
- In FY2025, shareholders' equity increased 21812.3% year-over-year.
- Ranks #172 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $99.0M | +21812.3% |
| FY2024 | -$456.0K | +99.0% |
| FY2023 | -$47.4M | +44.7% |
| FY2022 | -$85.8M | -18582.1% |
| FY2021 | -$459.0K | +94.1% |
| FY2020 | -$7.8M | -115.2% |
| FY2019 | $51.1M | -60.9% |
| FY2018 | $130.9M | +87.3% |
| FY2017 | $69.9M | -10.9% |
| FY2016 | $78.5M | +277.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026